AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc.

Citigroup Inc. cut its position in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 93.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 70,534 shares of the biotechnology company’s stock after selling 975,954 shares during the quarter. Citigroup Inc. owned 0.25% of AnaptysBio worth $2,160,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in ANAB. AQR Capital Management LLC raised its holdings in shares of AnaptysBio by 153.3% during the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock worth $558,000 after purchasing an additional 18,165 shares during the period. Savant Capital LLC bought a new position in shares of AnaptysBio in the 2nd quarter worth about $241,000. Los Angeles Capital Management LLC acquired a new position in shares of AnaptysBio in the 2nd quarter valued at about $334,000. Creative Planning boosted its holdings in shares of AnaptysBio by 26.9% in the 2nd quarter. Creative Planning now owns 16,854 shares of the biotechnology company’s stock valued at $374,000 after buying an additional 3,571 shares during the period. Finally, Intech Investment Management LLC bought a new stake in shares of AnaptysBio during the 2nd quarter valued at about $240,000.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Guggenheim reiterated a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Stifel Nicolaus lifted their target price on AnaptysBio from $56.00 to $85.00 and gave the company a “buy” rating in a research note on Thursday. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Barclays increased their price target on AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, UBS Group assumed coverage on AnaptysBio in a report on Wednesday, January 7th. They issued a “buy” rating and a $70.00 price target on the stock. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, AnaptysBio currently has a consensus rating of “Moderate Buy” and a consensus target price of $73.44.

AnaptysBio Stock Down 3.3%

ANAB stock opened at $55.41 on Friday. The stock has a market cap of $1.59 billion, a PE ratio of -106.56 and a beta of 0.32. The firm’s 50-day simple moving average is $50.27 and its 200 day simple moving average is $39.16. AnaptysBio, Inc. has a fifty-two week low of $15.32 and a fifty-two week high of $63.47.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The firm had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million. Equities analysts forecast that AnaptysBio, Inc. will post -6.08 EPS for the current fiscal year.

AnaptysBio declared that its board has initiated a stock buyback program on Friday, November 21st that allows the company to repurchase $100.00 million in shares. This repurchase authorization allows the biotechnology company to buy up to 9.6% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

Insider Activity at AnaptysBio

In related news, CFO Dennis Mulroy sold 2,515 shares of the stock in a transaction that occurred on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total value of $112,445.65. Following the completion of the transaction, the chief financial officer directly owned 21,852 shares of the company’s stock, valued at $977,002.92. This represents a 10.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul F. Lizzul sold 3,650 shares of the firm’s stock in a transaction that occurred on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $163,191.50. Following the completion of the sale, the insider owned 42,088 shares in the company, valued at approximately $1,881,754.48. This represents a 7.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 156,280 shares of company stock valued at $7,254,939. Company insiders own 33.50% of the company’s stock.

Trending Headlines about AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target sharply to $85 and kept a buy rating — a sizable upside vs. recent levels that likely boosted investor demand. Stifel raises PT to $85
• Positive Sentiment: Coverage noting a profitability turnaround and continued progress collecting Jemperli royalties supports a higher valuation narrative for ANAB. This fundamental story likely underpins recent buying interest. Assessing AnaptysBio valuation after profitability turnaround
• Positive Sentiment: ANAB hit a new 12‑month high following analyst upgrades, which can attract momentum and technical buying. ANAB hits new 12‑month high on analyst upgrade
• Negative Sentiment: HC Wainwright issued a mixed set of estimate changes: it lowered near‑term FY2026 and Q1/Q2 EPS forecasts (worse near‑term profitability) even as it raised several multi‑year estimates; the negative near‑term revisions could pressure sentiment despite the firm’s buy rating and $66 target. HC Wainwright estimate changes (MarketBeat summary)
• Neutral Sentiment: Short‑interest entries in recent reports are inconsistent/zero (showing NaN increases), indicating unreliable short‑interest data — not a clear driver of today’s move. (No reliable link provided in the filings.)

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.